VERA Projected Dividend Yield
Cl A/Vera Therapeutics Inc ( NASDAQ : VERA )Vera Therapeutics, Inc. is a late-stage biotechnology company. Co. is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Co. is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. 21 YEAR PERFORMANCE RESULTS |
VERA Dividend History Detail VERA Dividend News VERA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |